When the revised molecular-based diagnosis of metastatic PXA with BRAF V600E mutation was rendered, the patient was started on a combination of encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor). This evidence concerns the gene MAP2K7 and pleomorphic xanthoastrocytoma.